BioCentury
ARTICLE | Clinical News

pSivida submits MAA to EMA for Durasert

July 13, 2017 11:57 PM UTC

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) submitted an MAA to EMA for Durasert to treat posterior segment uveitis. The company says it is in discussions to out-license the 3-year sustained-release fluocino...

BCIQ Company Profiles

EyePoint Pharmaceuticals Inc.